Current views on rejection pathology in liver transplantation

Transplant International

Volumn 23, Issue 10, 2010, Pages 971-983

  Neil, Desley A H ^a,b   Hübscher, Stefan G ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antibody mediated rejection; central perivenulitis; de novo autoimmune hepatitis; idiopathic post transplant hepatitis; liver allograft rejection

Indexed keywords

ALLOANTIBODY; AMINOTRANSFERASE; AUTOANTIBODY; BILIRUBIN; COMPLEMENT COMPONENT C4D; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE T1; IMMUNOSUPPRESSIVE AGENT; STEROID;

ACUTE GRAFT REJECTION; AMINOTRANSFERASE BLOOD LEVEL; ARTERITIS; ARTERY DISEASE; ARTERY LESION; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BILE DUCT; BILIARY TRACT INFLAMMATION; BLAST CELL; CELL MATURATION; CENTRAL PERIVENULITIS; CHRONIC GRAFT REJECTION; CHRONIC HEPATITIS; CYTOPLASM; DRUG TOXICITY; EOSINOPHIL; FEVER; FIBROSIS; HEPATIC ARTERY; HEPATIC VEIN; HEPATITIS; HEPATITIS C; HISTOLOGY; HUMAN; HYPERGAMMAGLOBULINEMIA; IDIOPATHIC POST TRANSPLANT HEPATITIS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; ISCHEMIA; JAUNDICE; LIVER BIOPSY; LIVER CELL; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER PARENCHYMA; LIVER TRANSPLANTATION; LYMPHOCYTE; MACROPHAGE; MALAISE; MYOFIBROBLAST; NEUTROPHIL; NONHUMAN; PLASMA CELL; PORTAL VEIN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; REVIEW; T LYMPHOCYTE; THROMBOCYTE AGGREGATION; VIRUS HEPATITIS; VIRUS INFECTION;

ACUTE DISEASE; CHOLANGITIS; CHRONIC DISEASE; COMPLEMENT C4B; GRAFT REJECTION; HEPATITIS C; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER TRANSPLANTATION; PEPTIDE FRAGMENTS; RECURRENCE;

EID: 77956304560     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01143.x     Document Type: Review

References (99)

1. International Panel. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997 25 : 658.
2. Shaked A, Ghobrial RM, Merion RM, et al. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am J Transplant 2009 9 : 301.
3. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000 31 : 792.
4. Hubscher SG. Transplantation pathology. Semin Liver Dis 2009 29 : 74.
5. Hubscher SG, Portmann BC. Transplantation pathology. In : Burt AD, Portmann BC, Ferrel LD, eds. MacSween's Pathology of the Liver, 5th edn. Edinburgh : Churchill Livingstone, 2007 : 815 879.
6. Yeh MM, Larson AM, Tung BY, Swanson PE, Upton MP. Endotheliitis in chronic viral hepatitis: a comparison with acute cellular rejection and non-alcoholic steatohepatitis. Am J Surg Pathol 2006 30 : 727.
7. Demetris AJ, Adeyi O, Bellamy CO, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006 44 : 489.
8. Abraham SC, Freese DK, Ishitani MB, Krasinskas AM, Wu TT. Significance of central perivenulitis in pediatric liver transplantation. Am J Surg Pathol 2008 32 : 1479.
9. Krasinskas AM, Demetris AJ, Poterucha JJ, Abraham SC. The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transpl 2008 14 : 625.
10. Nakazawa Y, Jonsson JR, Walker NI, et al. Fibrous obliterative lesions of veins contribute to progressive fibrosis in chronic liver allograft rejection. Hepatology 2000 32 : 1240.
11. Sebagh M, Rifai K, Feray C, et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003 37 : 1293.
12. Hubscher SG, Buckels JA, Elias E, McMaster P, Neuberger J. Vanishing bile-duct syndrome following liver transplantation - is it reversible? Transplantation 1991 51 : 1004.
13. Padbury RT, Gunson BK, Dousset B, et al. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation 1993 55 : 789.
14. Lovell MO, Speeg KV, Halff GA, Molina DK, Sharkey FE. Acute hepatic allograft rejection: a comparison of patients with and without centrilobular alterations during first rejection episode. Liver Transpl 2004 10 : 369.
15. Sundaram SS, Melin-Aldana H, Neighbors K, Alonso EM. Histologic characteristics of late cellular rejection, significance of centrilobular injury, and long-term outcome in pediatric liver transplant recipients. Liver Transpl 2006 12 : 58.
16. Abraham SC, Poterucha JJ, Rosen CB, Demetris AJ, Krasinskas AM. Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests. Am J Surg Pathol 2008 32 : 965.
17. Tsamandas AC, Jain AB, Felekouras ES, Fung JJ, Demetris AJ, Lee RG. Central venulitis in the allograft liver: a clinicopathologic study. Transplantation 1997 64 : 252.
18. Hubscher SG. Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies. Liver Transpl 2008 14 : 596.
19. Krasinskas AM, Ruchelli ED, Rand EB, Chittams JL, Furth EE. Central venulitis in pediatric liver allografts. Hepatology 2001 33 : 1141.
20. Neil DA, Hubscher SG. Histologic and biochemical changes during the evolution of chronic rejection of liver allografts. Hepatology 2002 35 : 639.
21. Miloh T, Magid MS, Iyer K, Kerkar N, Morotti RA. Chronic rejection preceded by central perivenulitis, rapidly ensuing after liver transplantation in a pediatric patient. Semin Liver Dis 2009 29 : 134.
22. Quaglia AF, Del Vecchio BG, Greaves R, Burroughs AK, Dhillon AP. Development of ductopaenic liver allograft rejection includes a "hepatitic" phase prior to duct loss. J Hepatol 2000 33 : 773.
23. Gouw AS, van den Heuvel MC, van den Berg AP, Slooff MJ, de Jong KP, Poppema S. The significance of parenchymal changes of acute cellular rejection in predicting chronic liver graft rejection. Transplantation 2002 73 : 243.
24. Blakolmer K, Jain A, Ruppert K, et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation 2000 69 : 2330.
25. Ludwig J, Gross JB Jr., Perkins JD, Moore SB. Persistent centrilobular necroses in hepatic allografts. Hum Pathol 1990 21 : 656.
26. Allen KJ, Rand EB, Hart J, Whitington PF. Prognostic implications of centrilobular necrosis in pediatric liver transplant recipients. Transplantation 1998 65 : 692.
27. Turlin B, Slapak GI, Hayllar KM, Heaton N, Williams R, Portmann B. Centrilobular necrosis after orthotopic liver transplantation: a longitudinal clinicopathologic study in 71 patients. Liver Transpl Surg 1995 1 : 285.
28. D'Antiga L, Dhawan A, Portmann B, et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 2002 73 : 80.
29. Krukemeyer MG, Moeller J, Morawietz L, et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004 78 : 65.
30. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007 50 : 739.
31. Clouston AD, McCullen M, Fawcett J, Crawford DH Centrilobular hepatitis with elevated autoantibody titrers after liver transplantation - autoimmune hepatitis or a form of rejection? Hepatology 2002 36 : 658A.
32. Riva S, Sonzogni A, Bravi M, et al. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. Liver Transpl 2006 12 : 573.
33. Rodriguez-Mahou M, Salcedo M, Fernandez-Cruz E, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: long-term follow-up after liver transplantation. Transplantation 2007 83 : 1126.
34. Salcedo M, Rodriguez-Mahou M, Rodriguez-Sainz C, et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transpl 2009 15 : 530.
35. Aguilera I, Wichmann I, Sousa JM, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001 126 : 535.
36. Haga H, Egawa H, Fujimoto Y, et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl 2006 12 : 457.
37. Lunz JG III., Contrucci S, Ruppert K, et al. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol 2001 158 : 1379.
38. Evans HM, Kelly DA, McKiernan PJ, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006 43 : 1109.
39. Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Uemoto S, Manabe T. Idiopathic post-transplantation hepatitis following living donor liver transplantation, and significance of autoantibody titre for outcome. Transpl Int 2009 22 : 303.
40. Syn WK, Nightingale P, Gunson B, Hubscher SG, Neuberger JM. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007 13 : 984.
41. Shaikh OS, Demetris AJ. Idiopathic posttransplantation hepatitis? Liver Transpl 2007 13 : 943.
42. Ekong UD, Melin-Aldana H, Seshadri R, et al. Graft histology characteristics in long-term survivors of pediatric liver transplantation. Liver Transpl 2008 14 : 1582.
43. Neuberger J. Chronic allograft dysfunction: diagnosis and management. Is it always progressive? Liver Transpl 2005 11 : S63.
44. Maor-Kendler Y, Batts KP, Burgart LJ, et al. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation 2000 70 : 292.
45. Burra P, Mioni D, Cecchetto A, et al. Histological features after liver transplantation in alcoholic cirrhotics. J Hepatol 2001 34 : 716.
46. Herzog D, Soglio DB, Fournet JC, Martin S, Marleau D, Alvarez F. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl 2008 14 : 946.
47. Martin SR, Russo P, Dubois J, Alvarez F. Centrilobular fibrosis in long-term follow-up of pediatric liver transplant recipients. Transplantation 2002 74 : 828.
48. Mells G, Mann C, Hubscher S, Neuberger J. Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl 2009 15 : 931.
49. Seyam M, Neuberger JM, Gunson BK, Hubscher SG. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl 2007 13 : 966.
50. Kemnitz J, Gubernatis G, Bunzendahl H, Ringe B, Pichlmayr R, Georgii A. Criteria for the histopathological classification of liver allograft rejection and their clinical relevance. Transplant Proc 1989 21 : 2208.
51. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 31 : 929.
52. Manns MP, Bahr MJ. Recurrent autoimmune hepatitis after liver transplantation-when non-self becomes self. Hepatology 2000 32 : 868.
53. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998 351 : 409.
54. Heneghan MA, Portmann BC, Norris SM, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001 34 : 464.
55. Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007 7 : 955.
56. Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation 2001 71 : 664.
57. Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002 35 : 349.
58. Richter A, Grabhorn E, Helmke K, Manns MP, Ganschow R, Burdelski M. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin Transplant 2007 21 : 427.
59. Andries S, Casamayou L, Sempoux C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001 72 : 267.
60. Avitzur Y, Ngan BY, Lao M, Fecteau A, Ng VL. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation. J Pediatr Gastroenterol Nutr 2007 45 : 222.
61. Fiel MI, Agarwal K, Stanca C, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008 14 : 861.
62. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004 40 : 3.
63. Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl 2004 10 : 1166.
64. Miyagawa-Hayashino A, Haga H, Egawa H, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004 78 : 128.
65. Berardi S, Lodato F, Gramenzi A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007 56 : 237.
66. Cholongitas E, Samonakis D, Patch D, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006 81 : 488.
67. Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006 12 : 827.
68. Merli M, Gentili F, Giusto M, et al. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis? Dig Liver Dis 2009 41 : 345.
69. Dubel L, Farges O, Johanet C, Sebagh M, Bismuth H. High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection. Transplantation 1998 65 : 1072.
70. Lohse AW, Obermayer-Straub P, Gerken G, et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease - possible association with a steroid-resistant transplant rejection episode. J Hepatol 1999 31 : 149.
71. Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J Hepatol 2000 33 : 163.
72. Demetris AJ, Eghtesad B, Marcos A, et al. Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol 2004 28 : 658.
73. Regev A, Molina E, Moura R, et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004 10 : 1233.
74. Petrovic LM. Early recurrence of hepatitis C virus infection after liver transplantation. Liver Transpl 2006 12 : S32.
75. Schmeding M, Dankof A, Krenn V, et al. C4d in acute rejection after liver transplantation - a valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006 6 : 523.
76. Jain A, Ryan C, Mohanka R, et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin Transplant 2006 20 : 624.
77. Lorho R, Turlin B, Aqodad N, et al. C4d: a marker for hepatic transplant rejection. Transplant Proc 2006 38 : 2333.
78. Sadamori H, Yagi T, Iwagaki H, et al. Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol 2009 24 : 574.
79. Grassi A, Quarneti C, Ravaioli M, et al. Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transpl 2006 12 : 1673.
80. D'Errico-Grigioni A, Fiorentino M, Vasuri F, et al. Tissue hepatitis C virus RNA quantification and protein expression help identify early hepatitis C virus recurrence after liver transplantation. Liver Transpl 2008 14 : 313.
81. Unitt E, Gelson W, Davies SE, Coleman N, Alexander GJ. Minichromosome maintenance protein-2-positive portal tract lymphocytes distinguish acute cellular rejection from hepatitis C virus recurrence after liver transplantation. Liver Transpl 2009 15 : 306.
82. Khettry U, Huang WY, Simpson MA, et al. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum Pathol 2007 38 : 443.
83. Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988 132 : 489.
84. Demetris AJ, Jaffe R, Tzakis A, et al. Antibody mediated rejection of human liver allografts: transplantation across ABO blood group barriers. Transplant Proc 1989 21 : 2217.
85. Demetris AJ, Nakamura K, Yagihashi A, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992 16 : 671.
86. Rostron A, Carter V, Mutunga M, et al. A case of acute humoral rejection in liver transplantation: successful treatment with plasmapheresis and mycophenolate mofetil. Transpl Int 2005 18 : 1298.
87. Watson R, Kozlowski T, Nickeleit V, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006 6 : 3022.
88. Hadaya K, Ferrari-Lacraz S, Giostra E, et al. Humoral and cellular rejection after combined liver-kidney transplantation in low immunologic risk recipients. Transpl Int 2009 22 : 242.
89. Wilson CH, Agarwal K, Carter V, et al. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 2006 82 : 988.
90. Ratner LE, Phelan D, Brunt EM, Mohanakumar T, Hanto DW. Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. Transplantation 1993 55 : 814.
91. Haga H, Egawa H, Shirase T, et al. Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABO-incompatible liver transplantation. Liver Transpl 2004 10 : 16.
92. Egawa H, Ohdan H, Haga H, et al. Current status of liver transplantation across ABO blood-type barrier. J Hepatobiliary Pancreat Surg 2008 15 : 131.
93. Sakashita H, Haga H, Ashihara E, et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007 20 : 676.
94. Troxell ML, Higgins JP, Kambham N. Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med 2006 130 : 1489.
95. Testa G, Vidanovic V, Chejfec G, et al. Adult living-donor liver transplantation with ABO-incompatible grafts. Transplantation 2008 85 : 681.
96. Bu X, Zheng Z, Yu Y, Zeng L, Jiang Y. Significance of C4d deposition in the diagnosis of rejection after liver transplantation. Transplant Proc 2006 38 : 1418.
97. Sawada T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S. Lobular damage caused by cellular and humoral immunity in liver allograft rejection. Clin Transplant 2005 19 : 110.
98. Dankof A, Schmeding M, Morawietz L, et al. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch 2005 447 : 87.
99. Takaya S, Jain A, Yagihashi A, et al. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc 1999 31 : 2028.